Michalina Kolodziejczak

List of Publications by Year in Descending Order

29 papers	1,315 citations	14 h-index	31 g-index
31 ext. papers	1,630 ext. citations	6.2 avg, IF	4.06 L-index

#	Paper	IF	Citations
29	Procedural and 1-year outcomes following large vessel coronary artery perforation treated by covered stents implantation: Multicentre CRACK registry. *PLoS ONE*, **2021**, 16, e0249698	3.7	1
28	Safety and Efficacy of Embolic Protection Devices in Saphenous Vein Graft Interventions: A Propensity Score Analysis-Multicenter SVG PCI PROTECTA Study. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
27	Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy. *American Journal of Cardiology*, **2020**, 125, 727-734	3	2
26	Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry. *Mayo Clinic Proceedings*, **2019**, 94, 1457-1466	6.4	12
25	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2019**, 5, 47-54	6.4	9
24	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. *JAMA - Journal of the American Medical Association*, **2018**, 319, 1566-1579	27.4	205
23	Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. *European Journal of Cardio-thoracic Surgery*, **2018**, 53, 495-504	3	40
22	Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. *International Journal of Cardiology*, **2018**, 258, 59-67	3.2	8
21	Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. *International Journal of Cardiology*, **2018**, 269, 292-297	3.2	10
20	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. *Expert Review of Cardiovascular Therapy*, **2018**, 16, 419-429	2.5	4
19	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. *Annals of Internal Medicine*, **2018**, 168, 234-235	8	2
18	Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk. *JAMA - Journal of the American Medical Association*, **2017**, 317, 439	27.4	
17	Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease: A Meta-Analysis. *Circulation: Heart Failure*, **2017**, 10,	7.6	75
16	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. *Annals of Internal Medicine*, **2017**, 167, 103-111	8	30
15	Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. *International Journal of Cardiology*, **2017**, 227, 644-649	3.2	50
14	Off-pump coronary artery bypass grafting improves short-term outcomes in high-risk patients compared with on-pump coronary artery bypass grafting: Meta-analysis. *Journal of Thoracic and Cardiovascular Surgery*, **2016**, 151, 60-77.e1-58	1.5	122
13	Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. *Annals of Internal Medicine*, **2016**, 164, 600-7	8	40

List of Publications

12	From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2016**, 2, 44-53	6.4	17
11	Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature. *Atherosclerosis*, **2016**, 247, 189-92	3.1	14
10	Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. *Heart*, **2015**, 101, 1309-17	5.1	35
9	30-day mortality reduction with miniaturized extracorporeal circulation as compared to conventional cardiopulmonary bypass for coronary revascularization. Meta-analysis of randomized controlled trials. *International Journal of Cardiology*, **2015**, 198, 63-5	3.2	6
8	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. *Annals of Internal Medicine*, **2015**, 163, 40-51	8	281
7	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. *BMJ, The*, **2015**, 350, h1618	5.9	218
6	Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome. *JACC: Cardiovascular Interventions*, **2015**, 8, 201-213	5	50
5	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients. *Thrombosis and Haemostasis*, **2015**, 114, 933-44	7	9
4	Drug-Eluting Stents and Coronary Artery Disease **2015**, 495-524		
3	Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy?. *American Journal of Cardiovascular Drugs*, **2014**, 14, 79-87	4	22
2	Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *American Journal of Cardiology*, **2014**, 113, 1753-64	3	51
1	Things to avoid in meta-analysis. *European Journal of Preventive Cardiology*, **2013**, 20, 513	3.9	1